Funders

As one of IAVI’s founding donors, the Danish government, administered by Danida, has invested a total of DKK 162.5 million since 2001 to further capacity building and engagement of communities most at risk of HIV/AIDS, including women, girls, and key populations. This support most recently included a generous grant of DKK 20 million (US$3.18 million) from 2022-2025. 

Read the funder spotlight to learn more. 

EDCTP has supported IAVI’s HIV vaccine program since 2007, including our work with clinical trial partnerships, such as the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), and for our socio-behavioral research under the UPTAKE study. EDCTP has also supported a consortium in which IAVI is a partner to develop the H56:IC31 candidate, and to conduct advanced clinical development of IAVI’s Lassa fever vaccine candidate in West Africa. 

Read the funder spotlight to learn more. 

The German Federal Ministry of Education and Research through the KfW Development Bank has committed to contribute 9.2 million euros for the next five years to support an innovative public-private collaboration between IAVI and partners Biofabri and the Tuberculosis Vaccine Initiative to further their development of a safe, effective, affordable, and accessible tuberculosis vaccine.   

Read the funder spotlight to learn more. 

IAVI’s India program, established in 2001, began through an agreement with the Indian Council of Medical Research, Ministry of Health and Family with the goal of ensuring that India becomes a regional center of excellence in the research and development of vaccines. Steadfast support from the Government of India continues to expand IAVI’s life-saving work in India, especially related to HIV. 

Read the funder spotlight to learn more.

In 2010, the Government of Japan, in partnership with the World Bank, supported the development of IAVI’s first HIV vaccine candidate using a replicating vector. Japan continued to support IAVI’s HIV vaccine work focused on the vesicular stomatitis virus (VSV) technology. Japan’s support of the IAVI VSV program has enabled this platform technology to be applied to a range of pressing global health threats, now including COVID-19. 

Read the funder spotlight to learn more. 

The Ministry of Foreign Affairs of the Netherlands became a founding donor of IAVI in 1999 when the Netherlands joined the U.K. government in providing the earliest government support for a new public-private partnership initiative. Generous support through the Dutch Ministry of Foreign Affairs has helped IAVI to spur HIV/AIDS vaccine research through testing innovative concepts and shaping a robust pipeline of HIV vaccine an prevention candidates. 

Read the funder spotlight to learn more. 

The Norwegian government has been a longstanding supporter of IAVI’s mission and work. Between 2001 and 2015, through the Norwegian Development Agency (Norad), Norway generously provided IAVI flexible funding for HIV vaccine research (nearly US$30 million). Most recently, IAVI received funding through the Research Council of Norway from its Global Health and Vaccination Research (GLOBVAC) program for its innovative development of broadly neutralizing antibodies as HIV prevention products for women and girls in low- and middle-income countries. 

Read the funder spotlight to learn more.

The United Kingdom became IAVI’s first major public sector supporter in 1998 through the Department for International Development, now the Foreign, Commonwealth and Development Office. This support has helped IAVI make significant progress in HIV/AIDS vaccine research including cultivating groundbreaking research into powerful antibodies that can target a broader diversity of HIV subtypes. More recently, the U.K. government supported IAVI and its partners to significantly improve the efficacy, safety, and affordability of snakebite treatment in India and Africa through novel monoclonal antibody therapies. 

USAID, through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), has provided over 20 years of unwavering support to IAVI to drive the development of safe, effective, accessible, preventive HIV vaccines and biomedical prevention products for use throughout the world while strengthening local clinical research capacity in regions most devastated by the HIV epidemic. Most recently, ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic), a 10-year cooperative agreement with USAID through PEPFAR, builds on IAVI’s long-term partnership with USAID and capitalizes on the IAVI-fostered, sustainable, Africa- and India-based research partner network to build self-reliance. 

Read the funder spotlight to learn more.